NASDAQ:JAGX - Jaguar Health Stock Price, Forecast & News

Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."

Jaguar Health Inc (NASDAQ:JAGX) released its quarterly earnings results on Monday, November, 14th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.40) by $0.10. The biotechnology company earned $0.05 million during the quarter, compared to analysts' expectations of $0.10 million. Jaguar Health had a negative return on equity of 675.03% and a negative net margin of 771.25%. View Jaguar Health's Earnings History.

Jaguar Health is scheduled to release their next quarterly earnings announcement on Wednesday, April 8th 2020. View Earnings Estimates for Jaguar Health.

2 brokerages have issued twelve-month target prices for Jaguar Health's stock. Their forecasts range from $3.00 to $5.00. On average, they expect Jaguar Health's stock price to reach $4.00 in the next year. This suggests a possible upside of 601.8% from the stock's current price. View Analyst Price Targets for Jaguar Health.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jaguar Health.

News headlines about JAGX stock have been trending positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Jaguar Health earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Jaguar Health.

Some companies that are related to Jaguar Health include ProMetic Life Sciences (PFSCF), Inflarx (IFRX), Sierra Oncology (SRRA), NeuBase Therapeutics (NBSE), Northwest Biotherapeutics (NWBO), Helix Biopharma (HBPCF), Galectin Therapeutics (GALT), CELYAD SA/ADR (CYAD), PhaseBio Pharmaceuticals (PHAS), Cyclerion Therapeutics (CYCN), Adamas Pharmaceuticals (ADMS), Millendo Therapeutics (MLND), OASMIA PHARMACE/ADR (OASM), Chimerix (CMRX) and Galmed Pharmaceuticals (GLMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biopharmx (BPMX), Conatus Pharmaceuticals (CNAT), Cara Therapeutics (CARA), Precipio (PRPO), Neovasc (NVCN), PTC Therapeutics (PTCT), Biocept (BIOC), Cascadian Therapeutics (CASC), Cellectar Biosciences (CLRB) and SCYNEXIS (SCYX).

(JAGX) raised $22 million in an initial public offering (IPO) on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

Jaguar Health's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.21%). Company insiders that own Jaguar Health stock include James J Bochnowski, Jonathan B Siegel, Lisa A Conte and Nantucket Investments Ltd. View Institutional Ownership Trends for Jaguar Health.

JAGX stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Jaguar Health stock in the last two years include James J Bochnowski, Jonathan B Siegel and Lisa A Conte. View Insider Buying and Selling for Jaguar Health.

Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of JAGX stock can currently be purchased for approximately $0.57.

Jaguar Health has a market capitalization of $29.16 million and generates $4.42 million in revenue each year. The biotechnology company earns $-32,150,000.00 in net income (profit) each year or ($158.74) on an earnings per share basis. Jaguar Health employs 40 workers across the globe.View Additional Information About Jaguar Health.

The official website for Jaguar Health is http://www.jaguaranimalhealth.com/.

Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.